Bayer Launches Kerendia™ (finerenone), an Innovative Medicine to Slow Down Progression of Chronic Kidney Disease in Patients with Diabetes

Bayer today announced the launch of Finerenone under the brand name KerendiaTM in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease associated with type 2 diabetes. The recent Indian Chronic Kidney…